Larkspur Health Acquisition Corp.
LSPRW
NASDAQ Global Market0.18
USD
+0.03
- -
CIK
0001859007
CUSIP
51724W115
Return %
Stock
S&P500
1Y
50.00
26.53
3Y
50.00
76.60
5Y
50.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 100 Somerset Corporate Boulevard Bridgewater NJ United States of America 08807
- CIK
- 0001859007
- Similar Companies
- Business
- Larkspur Health Acquisition Corp. (NASDAQ:LSPRW) operates as a special purpose acquisition company, or blank-check company, with no significant independent operations other than seeking and completing a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting the biotechnology sector in the United States; it offers redeemable warrants exercisable at $11.50 per share, which commenced separate trading alongside its common stock and units following its initial public offering. Founded in 2021 and headquartered at 100 Somerset Corporate Blvd., 2nd Floor, Bridgewater, New Jersey, the company completed its $75 million initial public offering in December 2021, sponsored by Larkspur Health LLC with underwriting led by A.G.P./Alliance Global Partners and co-managed by Brookline Capital Markets. In its major strategic development, Larkspur consummated a reverse merger business combination with ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing VAR 200 for renal diseases and IC 100 for inflammatory diseases, on December 12, 2022, following shareholder approval on December 8, 2022, and an S-4 registration filing; post-merger, ZyVersa became the surviving public entity trading as ZVSA on Nasdaq, with approximately 99% shareholder redemptions leaving about $1 million in trust and aggregate committed financing of $10 million to support ZyVersa's clinical pipeline advancement. The LSPRW warrants persist as legacy securities related to the original SPAC structure, trading actively as of December 2025 with no reported further acquisitions, funding rounds, or operational shifts since the merger; the company maintains its Delaware incorporation and focuses solely on post-transaction warrant holder interests without ongoing biotechnology operations or geographic expansions beyond its U.S. target focus.